1. Home
  2. Search Clinical Trials
Search
Filters
Clear All
  • 49
  • 59
  • 6
  • 3
  • 497

Phase

  • 18
  • 14
  • 3
  • 14
  • 6
  • 15
  • 2
  • 439
  • 580
  • 230
  • 603
  • 11
  • 53
  • 26
  • 6
  • 608

Found 614 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Sort by:

IUCRO-0498; Role of Osteocytes in Myeloma Bone Disease

18 years - 95 years
All genders
The purpose of this study is to learn if substances that may cause bone destruction are increased in blood or bone marrow.
Learn More

A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent With Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva

18 years - 100 years
Female
This phase II trial studies how well giving radiation therapy together with gemcitabine hydrochloride and cisplatin work in treating patients with locally advanced squamous cell carcinoma of the vulva. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause …
Learn More

SARC024; A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma Osteogenic Sarcoma and Ewing/Ewing-like Sarcomas

18 years - 100 years
All genders
The purpose of this study is to examine regorafenib in a systematic fashion in patients with other forms of sarcoma.
Learn More

PHO-COG-CROOP-ADVL1312; A Phase 1/2 Study of AZD1775 (MK-1775) in Combination With Oral Irinotecan in Children Adolescents and Young Adults With Relapsed or Refractory Solid Tumors

1 years - 21 years
All genders
This phase I/II trial studies the side effects and best dose of WEE1 inhibitor MK-1775 and irinotecan hydrochloride in treating younger patients with solid tumors that have come back or that have not responded to standard therapy. WEE1 inhibitor MK-1775 and irinotecan hydrochloride may stop the growth of tumor cells …
Learn More

A Randomized Phase II Trial of Brentuximab Vedotin (SGN35 NSC# 749710) or Crizotinib (NSC#749005 Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)

21 years or below
All genders
This partially randomized phase II trial studies how well brentuximab vedotin or crizotinib and combination chemotherapy works in treating patients with newly diagnosed stage II-IV anaplastic large cell lymphoma.
Learn More

Diabetic Research Studies Recruitment Database

100 years or below
All genders
The purpose of the recruitment database is to store information on people who might be eligible to participate in current or future diabetes research studies.
Learn More

Screening and Recruitment of Panelists Who Wear Mandibular Partial Dentures for Participation in Subsequent Study(ies) Which Will Use an In-situ Biofilm Model.? (CO-1407011120407-NACT /14-I-098)?

18 years - 78 years
All genders
The purpose of this study is to screen persons who wear a lower partial denture to see if they might qualify to participate in future partial denture studies that will look at biofilm growth and ways of removing it.
Learn More

Generation of Induced Pluripotent Stem Cells from Subjects with Darier-White Disease

3 years - 100 years
All genders
The purpose of this study is to serve as a research resource to collect blood samples and information in order to study the cells that produce insulin.
Learn More

Genotype-directed Phase II Study of Irinotecan Dosing in Metastatic Colorectal Cancer (mCRC) Patients Receiving FOLFIRI + Bevacizumab

18 years - 100 years
All genders
This study involves standard combination chemotherapy treatment for colon cancer, 5-Fluorouracil (5FU), leucovorin and irinotecan (known as FOLFIRI), plus bevacizumab (Avastin). The study is designed to test the FOLFIRI regimen based on certain characteristics of a person's genetic makeup or "genes". Genes are made of DNA and determine not only …
Learn More

A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)

2 years - 30 years
All genders
This randomized phase III clinical trial compares how well combination chemotherapy works when given with or without bortezomib in treating patients with newly diagnosed T-cell acute lymphoblastic leukemia or stage II-IV T-cell lymphoblastic lymphoma.
Learn More
81 - 90 of 614